PROSILIC
LIVE

Serial Number

79213643

Owner

SISAF Ltd

Attorney

Craine, Dean A

Filing Date

Mar 8, 2017

Add to watchlist:

No watchlists yet
View on USPTO

PROSILIC Trademark

Serial Number: 79213643 • Registration: 5614010

PROSILIC is a trademark filed by SISAF Ltd on March 8, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

SISAF Ltd (10 trademarks)

3 Huxley Road,

Entity Type: 99

Trademark Details

Filing Date

March 8, 2017

Registration Date

November 27, 2018

Published for Opposition

September 11, 2018

Goods & Services

Chemical preparations for use in industry; chemical preparations for scientific purposes; biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and beverages and pharmaceutical preparations for topical use; reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; silicon for use in industry, science and research; pure non-metallic silicon sold in nanoparticle form for use in industry, science and research; pure non-metallic porous silicon sold in nanoparticle form for use in industry, science and research; silicon for use in stabilising of enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes

Chemicals and chemical preparations, namely, antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations; antifungal pharmaceutical preparations, anti-fibrotic pharmaceutical preparations; chemicals and chemical preparations, namely, pharmaceutical preparation for skin care; chemicals and chemical preparations, namely, pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory and pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney and nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, [ winkles ] * wrinkles *, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals skin care preparations; drug delivery agents in the form of powders, liquids and gels that provide controlled release of the active ingredients for a wide variety of pharmaceutical, nutraceutical and veterinary products

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
May 18, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Apr 15, 2026 NA71
REGISTERED-SEC.71 ACCEPTED
Apr 15, 2026 71AG
PETITION TO DIRECTOR GRANTED
Apr 9, 2026 PCGR
ASSIGNED TO PETITION STAFF
Mar 25, 2026 APET
TEAS PETITION TO DIRECTOR RECEIVED
Oct 21, 2025 TPDR
POST REGISTRATION ACTION MAILED - SEC.71
Sep 18, 2025 PR71
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
Sep 18, 2025 NCP7
CANCELLED SEC. 7 - PARTIAL
Sep 18, 2025 C7P.
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Sep 9, 2025 EROP
TEAS SECTION 7 REQUEST RECEIVED
Sep 3, 2025 ES7R
POST REGISTRATION ACTION MAILED - SEC.71
May 28, 2025 PR71
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 27, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC.71
Mar 10, 2025 PR71
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 10, 2025 APRE
TEAS SECTION 71 RECEIVED
Oct 14, 2024 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 27, 2023 REM3
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Jan 30, 2020 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 6, 2020 INPR
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 25, 2019 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 24, 2019 APRE
TEAS SECTION 7 REQUEST RECEIVED
Apr 4, 2019 ES7R
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 29, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 7, 2019 FICS
FINAL DISPOSITION PROCESSED
Mar 7, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 28, 2019 FICR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 14, 2018 TCCA
REGISTERED-PRINCIPAL REGISTER
Nov 27, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 11, 2018 NPUB
PUBLISHED FOR OPPOSITION
Sep 11, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Sep 7, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 22, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 22, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 22, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 6, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 6, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 6, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 6, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 6, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 28, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 28, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 12, 2018 GNFN
FINAL REFUSAL E-MAILED
Mar 12, 2018 GNFR
FINAL REFUSAL WRITTEN
Mar 12, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 15, 2018 CRFA
ASSIGNED TO LIE
Feb 14, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 7, 2018 TROA
REFUSAL PROCESSED BY IB
Aug 25, 2017 RFNT
APPLICATION FILING RECEIPT MAILED
Aug 11, 2017 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 10, 2017 RFCS
REFUSAL PROCESSED BY MPU
Aug 10, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 9, 2017 RFCR
NON-FINAL ACTION WRITTEN
Aug 8, 2017 CNRT
ASSIGNED TO EXAMINER
Aug 7, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 7, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 3, 2017 REPR